U.S. Pain Management Drugs Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 31.66 Bn

Forecast Year, 2035

USD 44.90 Bn

CAGR, 2026 - 2035

3.56%

Report Coverage

U.S.

What is the U.S. Pain Management Drugs Market Size?

The U.S. pain management drugs market size was calculated at USD 32.79 billion in 2025 and is predicted to increase from USD 33.84 billion in 2026 to approximately USD 46.50 billion by 2035, expanding at a CAGR of 3.56% from 2026 to 2035. The U.S. pain management drugs market is driven by rising demand for effective non-opioid pain treatments and growing concerns over opioid dependence.

Market Highlights

• By drug class, the opioids segment is expected to dominate the market over the forecast period.
• By indication, the arthritic pain segment is expected to capture the largest market share during the forecast period.
• By distribution channel, the hospital pharmacy segment held the largest share of the market in 2025. The segment is observed to sustain the position throughout the predicted timeframe.

Market Overview

The U.S. pain management drugs market offers series of therapeutics in order to manage the pain caused by certain health concerns. Multiple sclerosis, stomach ulcers, osteoarthritis, chronic arthritis, diabetic neuropathy, fibromyalgia, and cancer are among the conditions that might be uncomfortable. Acute pain might last for a short while, whereas chronic pain lasts for a longer period.

Acute discomfort might be minor and subside quickly, or it can last for several weeks or months. Age-related bone and joint disorders, nerve damage, and even injuries can result in chronic pain. Many medications are used to treat pain arising from inflammation in reaction to pathogens or chemical agents (nociceptive pain), tissue injury, or damage to the nerves (neuropathic pain).

The number of Americans 65 and older grew around five times faster than the country as a whole during the 100 years between 1920 and 2020, according to the US Census Bureau. Senior citizens made up 55.8 million of the US population in 2020 or 16.8% of the overall population.

How is AI Transforming the U.S. Pain Management Drugs Market?

Artificial Intelligence is rapidly altering the U.S. pain management drugs market by enabling the development of new drugs, designing clinical trials, and introducing new personalised care strategies. High-accuracy AI-powered analytics will support research for the discovery of new non-opioid drug candidates, prediction of patient outcomes, improvement of outcomes, and become faster and cheaper to develop. Machine learning is becoming increasingly popular in the pharmaceutical industry, due to its efforts to use real-world patient data in health care, precision medicine, and pharmacovigilance.

U.S. Pain Management Drugs Market Growth Factors

• The rising incidence of chronic conditions, such as arthritis, neuropathy, and musculoskeletal disorders, contributes to the demand for pain management drugs.
• Ongoing research and development efforts to create novel pain management drugs with improved efficacy and fewer side effects can stimulate the U.S. pain management drugs market's growth. Pharmaceutical companies invest in developing new formulations and delivery methods to enhance patient outcomes.
• Increased awareness among healthcare professionals and patients about the importance of effective pain management can drive the adoption of pain management drugs. Education initiatives may focus on the proper use of medications and alternative therapies.

U.S. Pain Management Drugs Market Trends

• Growing shift from opioid drugs to safer non-opioid alternatives.
• A rising number of chronic pain patients, increasing long-term medication use.
• Higher demand for topical pain products like patches, creams, and gels.
• More doctors are prescribing combination therapies to reduce opioid dependence.
• Increasing use of cannabis and CBD-based products for various types of pain.
• Rapid growth of biologic drugs, especially for migraines and nerve pain.
• Wider use of digital tools and apps to guide pain treatment choices.
• Focus on safer opioid formulations with abuse-deterrent features.
• Strong rise in over-the-counter pain relievers for self-care needs.

How are Government Initiatives Supporting the U.S. Pain Management Drugs Market?

Regulatory support, growth of pain research funding, and awareness campaigns by government initiatives are helping to fuel the market in the U.S. Healthcare providers are pushing alternative strategies to pain management, such as non-opioid use, with the U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH).

• The FDA approved an oral tablet in the form of Vertex Pharmaceuticals' drug Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain. Journavx is the first member of a new class of alternative pain analgesics - non-opioid - to be approved by the FDA in more than 20 years. (Source: https://www.iasp-pain.org)

Market Outlook

• Industry Growth Overview: The U.S. pain management drugs market is growing due to postoperative discomfort, arthritis, and chronic pain are becoming more common. For a speedier recovery, patients and medical professionals still depend on efficient pain management solutions. Increased awareness of pain-related conditions and increased access to treatment both contribute to growth.
• Sustainability Trends: Pharmaceutical companies are working toward greener manufacturing, reducing chemical waste, and using eco-friendly packaging. There is also a push for safer formulations with fewer side effects. Digital prescription systems are helping reduce paper waste and support responsible medication use.
• Major Investors: Major investors include large pharmaceutical companies like Pfizer, Johnson & Johnson, Eli Lilly, and Teva, who continue to expand R&D in non-opioid pain treatments. Funding also flows into biotech firms developing targeted pain therapies. Investors are prioritizing drugs that offer strong relief with lower addiction risk.

Market Scope

Market Dynamics

Driver

Growing Burden of Chronic and Acute Pain Conditions

Chronic and acute pain are emerging diseases and are contributing factors for the expansion in the U.S. Pain in various forms, such as rheumatism-related pain, cancer-related pain, neuropathic pain, musculoskeletal pain, and post-surgical pain, afflicts millions of Americans and is a potential long-term requirement for effective treatments. Improvements in diagnostic technology, early intervention, and treatment are occurring because of the growing awareness of the importance of pain management.

Restraint

Regulatory Challenges and Concerns Over Drug Dependence

Compliance with strict legislation on pain drugs and increasing awareness of drug abuse and addiction are still limiting the market growth. There have been new rules and restrictions enacted for healthcare providers when it comes to prescription, monitoring, and authorization of medications. The pharmaceutical industry is facing regulatory hurdles and safety issues with new pain medication drugs.

Opportunity

Advancement of Innovative Drug Delivery and Formulation Technologies

Developing advanced formulation and delivery methods presents a tremendous growth opportunity in the U.S. pain management drugs market. These are helping to boost the effectiveness of the therapy and minimise side effects and patient compliance (e.g., transdermal patches, sustained release, liposomal drug delivery systems, targeted release systems). These technologies enable better pain control without the requirement to dose to control pain and thereby achieve better patient outcomes.

Segments Insights

Drug Class Insights

How did the NSAIDs Segment Lead the Market?

The NSAIDs segment led the U.S. pain management drugs market in 2025, due to their efficacy in relieving acute, chronic, and inflammatory pain. NSAIDs are commonly used to treat musculoskeletal pain, post-operative pain, and arthritis as a first-line drug. These factors include the growing number of chronic diseases, the elderly population, and the availability of over-the-counter products supporting the segment's growth.

The opioids segment is expected to grow at the fastest rate during the forecast period as it is very effective for both acute and chronic pain, for cancer, and after surgery. Market growth continues through the launch of surgical/visiting growth, growing cancer diagnoses, and increasing need for palliation. Significant advances in both technology and controlled prescribing are occurring, which have led to safety and efficacy.

Indication Insights

The Chronic Musculoskeletal Pain Segment Dominates the U.S. Pain Management Drugs Market in 2025

The chronic musculoskeletal Pain segment dominated the market with a major share in 2025, primarily due to the high prevalence of osteoarthritis, low back pain, and other age-related musculoskeletal disorders. The increased number of elderly patients, as well as the weight-related increase in joint disease, has led to a significant increase in the need for long-term pain management treatments. Patients need to have continuous, pharmacologically supported mobility and be supported in maintaining their quality of life to support the point of continuous use of the drug.

The acute pain segment is projected to grow at the fastest rate during the forecast period due to a high number of surgical procedures, trauma cases, and treatments of short-term injuries. New research to develop effective pain relievers that can act quickly and can be utilised to improve the patient's recovery and shorten the length of hospital stay. Innovation in the field of acute pain management is accelerating, as there's a growing need for alternative, non-opioid methods that can offer safer therapies.

Distribution Channel Insights

Retail pharmacies held the Largest Share of the Market in 2025

The retail pharmacies segment held the largest share of the U.S. pain management drugs market in 2025, as they are broadly accessible and convenient. They're an important distribution route for both prescription drugs to alleviate pain and OTC pain relievers, as well as a driver for pain management delivery. Retail pharmacies will offer pharmacist consultation, counselling on medication use, and refill services, which meet the needs of patients to ensure adherence to treatment plans.

The online pharmacy segment is anticipated to grow at a significant rate during the forecast period, because of the ease of online distribution, privacy, and low cost of drugs. With the increasing convenience of digital healthcare services and telemedicine, even pharmacists can provide prescriptions and medications to individuals without having to see them in person. It's particularly beneficial for patients who are elderly or have poor mobility or who require regular pain management care.

Country-Level Analysis

• Growing Burden of Chronic Pain Conditions: The prevalence of chronic pain disorders, e.g., arthritis, osteoarthritis, neuropathic pain, cancer pain, and low back pain is increasing in the United States, and so is the demand for pain management medicines, particularly among older adults.
• Rising Demand for Non-Opioid Therapies: More awareness about the risks of opioid addiction and overdose is contributing to the rise in non-opioid pain treatments. The pharma industry is making efforts to create safer analgesics (pain relievers) and new drugs to treat pain.
• Drug Innovation and Product Development: As new classes of drugs, new abuse deterrent technologies, extended release, and targeted drug delivery systems continue to be developed, patient outcomes continue to improve, while treatment options are increasing.
• Strategic Partnerships and Research Collaborations: More pharmaceutical companies are seeking to partner with biotechnology businesses, universities, and research institutes for the fast development of novel pain drugs, clinical development, and commercialisation.
• Expansion of Outpatient and Ambulatory Care Services: The ambulatory surgical centres and outpatient treatment centres are emerging, and new challenges are being created with the need for effective pain management to ensure patients will be able to recover and return to a convenient lifestyle.
• Government Support and Regulatory Initiatives: Government support and a faster approval process for new drugs and increased government funding for research are creating opportunities and changing the landscape for alternative pain management strategies.

Competitive Landscape

The U.S. pain management drugs market has major key players such as Novartis AG, Eli Lilly & Company, Abbott Laboratories, Pfizer Inc., Viatris, and Merck & Co., competing with them by introducing innovations and expanding their portfolios. Such strategies include product approvals, partnerships, collaborations, acquisitions, and building market presence, which are being adopted by these companies. Their focus is more directed toward non-opioid pain treatment, has advanced drug delivery systems, and next-generation treatments.

Competition exists in terms of the effectiveness of the product, its safety, adherence to regulations, price, and patient need. Companies are spending a lot of money on research and development to find and develop new drugs that can help to lessen opioid addiction and enhance treatment results.

U.S. Pain Management Drugs Market Companies

• Teva Pharmaceutical
• Pfizer
• Abbott
• Mallinckrodt Pharmaceuticals
• Endo International
• GlaxoSmithKline
• AstraZeneca
• Depomed
• Merck
• Novartis

Recent Developments

• In May 2025, UPMC Enterprises and Redesign Health formed a new company, Glimmer Health, to continue the vision of a new, personalised, comprehensive pain care delivery system. The company collaborates with primary care physicians to maximise patient results and the implementation of available and effective pain treatment solutions. (Source: https://www.upmc.com)
• In January 2025, Journavx (suzetrigine) is the first novel non-opioid pain medication class approved by the U.S. FDA in almost 20 years to treat moderate to severe acute pain. It is a new drug that is prescribed as a 50mg tablet taken twice daily following an initial 'loading dose'. (Source: https://www.fda.gov)
• In May 2023, Zoetis Inc. announced that LibrelaTM (bedinvetmab injectable) has been authorized by the U.S. Food and Drug Administration (FDA) for the management of pain in dogs suffering from osteoarthritis (OA). The first and only monthly anti-NGF monoclonal antibody medication for canine OA pain is called Librela, and it is both safe and effective in managing dogs' OA pain symptoms over the long term, which can enhance their mobility and general quality of life.

Segments Covered in the Report

By Drug Class

• NSAIDs
• Opioids
• Anesthetics
• Antidepressants
• Anticonvulsants
• Others

By Indication

• Arthritic Pain
• Neuropathic Pain
• Chronic Back Pain
• Post-Operative Pain
• Cancer Pain
• Others

By Distribution Channel

• Online Pharmacy
• Retail Pharmacy
• Hospital Pharmacy